Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: A pilot study

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.

Original languageEnglish
Pages (from-to)254-260
Number of pages7
JournalOcular Immunology and Inflammation
Volume18
Issue number4
DOIs
StatePublished - Aug 1 2010

Fingerprint

Neoplasms
interferon alfa-2b
Therapeutics
Recurrence
Injections
peginterferon alfa-2b

Keywords

  • Conjunctival intraepithelial neoplasia
  • Ocular surface squamous neoplasia
  • Pegylated interferon

ASJC Scopus subject areas

  • Ophthalmology
  • Immunology and Allergy

Cite this

Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia : A pilot study. / Karp, Carol; Galor, Anat; Lee, Yunhee; Yoo, Sonia H.

In: Ocular Immunology and Inflammation, Vol. 18, No. 4, 01.08.2010, p. 254-260.

Research output: Contribution to journalArticle

@article{27b57bc707f5447cafb043d1772e7bf5,
title = "Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: A pilot study",
abstract = "Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.",
keywords = "Conjunctival intraepithelial neoplasia, Ocular surface squamous neoplasia, Pegylated interferon",
author = "Carol Karp and Anat Galor and Yunhee Lee and Yoo, {Sonia H}",
year = "2010",
month = "8",
day = "1",
doi = "10.3109/09273948.2010.486687",
language = "English",
volume = "18",
pages = "254--260",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia

T2 - A pilot study

AU - Karp, Carol

AU - Galor, Anat

AU - Lee, Yunhee

AU - Yoo, Sonia H

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.

AB - Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.

KW - Conjunctival intraepithelial neoplasia

KW - Ocular surface squamous neoplasia

KW - Pegylated interferon

UR - http://www.scopus.com/inward/record.url?scp=77954869515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954869515&partnerID=8YFLogxK

U2 - 10.3109/09273948.2010.486687

DO - 10.3109/09273948.2010.486687

M3 - Article

C2 - 20662655

AN - SCOPUS:77954869515

VL - 18

SP - 254

EP - 260

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

IS - 4

ER -